Introduction
============

Cancer is recognized as one of the most common causes for death world over. Patients suffering from cancer live a poor quality of life and it impacts a serious socio-economic burden on the health care system \[[@r1]\]. The underlying causes of this malignant disease remain undetermined. Studies have suggested that susceptible genes, a few high penetrance, numerous moderate and some low penetrance, may play a significant role in cancer development \[[@r2]\]. However, these factors alone are not sufficient for progression of carcinogenesis, suggesting consideration of role of changes in epigenetic status in carcinogenesis.

Aberrant DNA methylation pattern is one of the many epigenetic changes in human cancers. The DNA methylation silences a number of tumor suppressor genes in cancer cells around the promoter regions on CpG islands and its level is lower in cancer cells than in normal cells \[[@r3]\]. A family of DNA methyltransferases (DNMTs), including DNMT1, DNMT3A and *DNMT3B*, mediate the DNA methylation in human cells \[[@r4], [@r5]\]. Among these three active forms, *DNMT3B,* which encodes DNA methyltransferase-3B and is located on chromosome 20q11.2, is a major mammalian DNA methyltransferase primarily responsible for de novo methylation process, thereby, playing oncogenic role in malignancies \[[@r6]\].

Over expression of *DNMT3B* has been reported in carcinogenesis and it plays a crucial role in tumorigenesis \[[@r7], [@r8]\]. Single nucleotide polymorphisms (SNPs) located within the genes of DNMTs can change their expression levels which may affect the development of various cancers \[[@r9]\]. A SNP cytosine (C) \>T (Thymine) C46359T (Gen Bank accession no. AL035071) located upstream of the transcription start site at the -149 base pair of the promoter region is reported to increase the promoter activity \[[@r10]\]. The association between *DNMT3B* -149 C\>T polymorphism with cancer risk has been widely studied in several types of cancers but till now no consensus has been achieved because of conflicting results \[[@r10]-[@r27]\]. It is possible that small sample size with low power contributed to the false-positive or false-negative findings, indicating the significance of sample size as a methodological concern in the genetic association studies. Therefore, the use of meta- and pooled-analysis which combines the results from individual studies, both with statistically significant and non-significant observations, and weighs them by their precision as a function of sample size \[[@r28]\], is warranted. We in this study did a systematic meta-analysis by pooling all the published studies and examining the results to evaluate the overall possibility of a *DNMT3B* -149 C\>T gene variation with cancer risk.

Materials and Methods
=====================

Identification and Eligibility of Relevant Studies
--------------------------------------------------

We performed a systematic literature search through PubMed (Medline), EMBASE web databases covering all research articles published till June, 2015 using the following key words alone or in combination: "*DNMT3B* gene AND (variant OR polymorphism OR mutation) AND Cancer or Carcinoma or malignancy". The studies showing potential relevance were examined for genetic association by scrutinizing their titles and abstracts. The studies matching with the above mentioned eligible criteria were retrieved and included in this meta-analysis.

Inclusion and Exclusion Criteria
--------------------------------

The eligible studies had to meet the following criteria in order to minimize heterogeneity and facilitate the proper elucidation of results: (i) evaluation of the *DNMT3B* -149 C46359T (C\>T) and risk of cancer, (ii) case-control study, (iii) recruited pathologically confirmed cancer cases and cancer free controls, (iv) availability of subject's genotype frequency, and (v) in English language. In case a study of same case series was published in more than one article, the study containing largest number of subjects was included. The main exclusion criteria were: (i) data overlapping, and (ii) studies including cases only and review articles.

Data Extraction and Quality Assessment
--------------------------------------

Two independent investigators assessed the methodological quality, extracted and abstracted the data for each retrieved and eligible study using a standard protocol. A data-collection form was used to ensure the accuracy of the data following the inclusion criteria listed above. Any disagreement on the collected data from the retrieved studies was discussed fully to reach a consensus. The following were the main characters abstracted from the included studies: first author's name, publication year, country of origin, source and number of cases and controls, type of study, and genotype frequencies.

Statistical Analysis
--------------------

The pooled odds ratios (ORs) and their corresponding 95% confidence intervals (CIs) were calculated for each study to evaluate the relation between the *DNMT3B* -149 C\>T polymorphism and the risk of cancer. The association was examined using allelic, recessive and dominant genetic models. The chi-square based Q-test was used to examine the heterogeneity assumptions \[[@r29]\], where *p*-value less than 0.05 indicated lack of heterogeneity among the studies. When the heterogeneity among studies was not significant, pooled ORs were calculated by the fixed-effects model \[[@r30]\]; otherwise, random-effects model was used \[[@r31]\]. To quantify inter-study variability (ranged between 0% and 100%, where a value of 0% indicates no observed heterogeneity and larger values indicate an increasing degree of heterogeneity), I^2^ statistics was employed \[[@r32]\]. In the control group, the Hardy--Weinberg equilibrium (HWE) was measured via the chi-square test to find the departure of DNMT3B -149 polymorphism frequencies from the expected frequencies. To test the publication bias, funnel plot asymmetry was estimated by the Egger's linear regression test, where t test was used to determine the significance of the intercept and *p-*value \<0.05 was considered to be representing statistically significant publication bias \[[@r33]\]. The comprehensive meta-analysis (CMA) version 2 software (Biostat Inc., USA) was used to perform all the statistical analyses for this study. The comparison of various meta-analysis programs is available on the web through <http://meta-analysis.com/pages/comparisons.html>.

Results
=======

Characteristics of Published Studies
------------------------------------

Through literature search from the PubMed (Medline) and the EMBASE database, a total of 63 articles were included initially. These articles were examined by reading their titles, abstracts, and the full texts, and their suitability for meta-analysis was also checked. For other potentially relevant articles to be included in the study, the reference list of these retrieved articles was also screened. Further, survival studies on the *DNMT3B* polymorphism patients, and those indicating therapeutic response were excluded. After following the stringent criteria in article search, only case-control or cohort design studies, with frequency of all the three genotypes available, were included. Careful screening and application of the above mentioned stringent inclusion and exclusion criteria resulted in 18 eligible original published studies to be included in the study (Table **[1](#T1){ref-type="table"}**). The detailed flowchart for this selection process is shown (Fig. **[1](#F1){ref-type="fig"}**). The genotype distribution for all the subjects, HWE (*p*-values) for the controls, and cancer susceptibility is depicted (Table **[2](#T2){ref-type="table"}**).

Publication Bias
----------------

To evaluate the publication bias among the included studies, the Begg's funnel plot and Egger's test were performed. No evidence of publication bias for all the comparison models was observed by the shape of the funnel plots and the results of Egger's test (Table **[3](#T3){ref-type="table"}**).

Test of Heterogeneity
---------------------

The heterogeneity among the included studies was tested by Q-test and I^2^ statistics. We observed heterogeneity in two genotype models, heterozygous (CT vs. CC) and recessive (TT vs CC+CT), in overall analysis. These were included for the analysis and thus random effect model was applied to calculate their pooled ORs and 95% CI (Table **[3](#T3){ref-type="table"}**).

Meta-analysis of *DNMT3B* -149 (C\>T) Polymorphism and Cancer Susceptibility
----------------------------------------------------------------------------

The eighteen included studies, accumulating to a total of 7618 controls and 5583 cancer cases, were pooled together and used to assess the overall association between the *DNMT3B* -149 C\>T polymorphism and cancer risk. Overall, none of the genetic models - allele (T vs. C: p = 0.303; OR= 1.032, 95% CI = 0.972-1.097), homozygous (TT vs. CC: p=0.336; OR= 1.063, 95% CI = 0.939--1.204), heterozygous (CT vs. CC: p=0.802; OR= 1.022, 95% CI = 0.860-1.216), dominant (TT vs. CC+ CT: p= 0.298; OR= 1.101, 95% CI = 0.919-1.319) and recessive (TT+CT vs. CC: p= 0.656; OR= 1.021, 95% CI = 0.931-1.121) showed any risk of developing overall cancer (Fig. **[2](#F2){ref-type="fig"}**).

Sensitivity Analysis
--------------------

For sensitivity analysis, one study at a time was excluded from the analysis to assess its influence on the pooled OR. No individual study affected the pooled OR significantly indicating the relative stability of this meta-analysis.

Subgroup Analysis by Ethnicity
------------------------------

We stratified the included studies into two subgroups (Asian and Caucasian) by participant's ethnicity. We did not observe any heterogeneity in all the five genetic models in Asian subgroup, hence fixed effect model was applied. Also, no publication bias existed in this subgroup (Table **[3](#T3){ref-type="table"}**). We observed no significant cancer risk with all the genetic models - allele (T vs. C: p=0.324; OR=1.148, 95% CI=0.873 - 1.510), homozygous (TT vs. CC: p=0.724; OR=1.119, 95% CI=0.600 - 2.089), heterozygous (CT vs. CC: p=0.733; OR=1.091, 95% CI=0.660 - 1.806), recessive (TT+CT vs. CC: p=0.694; OR=1.100, 95% CI=0.685 - 1.765) and dominant (TT vs. CC+CT: p=0.272; OR=1.249, 95% CI=0.840 - 1.857) as shown (Fig. **[3](#F3){ref-type="fig"}**).

Based on heterogeneity, random effect model was applied in three genetic models in Caucasian population - CT vs. CC; TT+CT vs. CC; and TT vs. CC+CT. However, publication bias did not exist in this subgroup also (Table **[3](#T3){ref-type="table"}**). We found no significant association with cancer risk under all genetic models - allele (T vs. C: p=0.163; OR=1.052, 95% CI=0.980 - 1.130), homozygous (TT vs. CC: p=0.137; OR=1.117, 95% CI=0.965 - 1.291), heterozygous (CT vs. CC: p=0.842; OR=1.024, 95% CI=0.813 - 1.290), Recessive (TT+CT vs. CC; p=0.594; OR=1.050, 95% CI=0.877 - 1.257), and dominant (TT vs. CC+CT; p=0.428; OR=1.102, 95% CI=0.867 - 1.402) as shown (Fig. **[4](#F4){ref-type="fig"}**). Sensitivity analysis was also performed for both the ethnicities and the pooled OR was not affected significantly by any of the individual study.

Discussion
==========

DNA methylation plays an important role in the pathogenesis of malignancies by altering the expression of genes involved in cell proliferation and differentiation \[[@r34]\]. The DNMTs are believed to act cooperatively and maintain DNA methylation patterns, and their altered expression in tumors may partly explain aberrant methylation phenomenon in cancerous tissues or cells \[[@r35]\]. A number of studies have suggested the aberrant role of DNA methylation in carcinogenesis \[[@r36]\]. Studies have shown that the *DNMT3B* -149 C\>T polymorphism may change the enzyme methylation activity and thereby influence the cancer susceptibility. This has resulted in increasing number of case-control studies in the literature performed to explore the possible association between *DNMT3B* -149 C\>T polymorphism and modulations of cancer risk in different populations around the world. But, inconsistency in their results has been found prevalent which incited us to assess their overall contribution in understanding the role of this polymorphism in genetic susceptibility to cancer. Also, the inability to reproduce the results of several of these genetic variation studies has been reported, suggesting a large number of "false positive" reports \[[@r37]\]. Therefore, we performed the meta-analysis, in order to improve the statistical power and reliability in conclusion, of eighteen studies of *DNMT3B* -149 C\>T polymorphism and overall cancer susceptibility. A meta-analysis is an emerging and powerful tool for analyzing cumulative data from different research studies with small sample sizes and low statistical power \[[@r38]\].

The overall pooled results of this meta-analysis revealed no increased or decreased influence of *DNMT3B* -149 C\>T polymorphism on overall cancer risk in all the genetic models. When we stratified the selected studies by the ethnicity- Asian and Caucasian populations, again we failed to detect significant risk of this polymorphism on cancer risk. These findings clearly indicate that the *DNMT3B* -149 C\>T polymorphism may not be a potential susceptibility factor to cancer and its development in both Asian and Caucasian populations. However, the precise biological mechanism of this relationship remains unclear. In our opinion, the possible explanation may be that the *DNMT3B* -149 C\>T polymorphism is not involved directly in cancer susceptibility but may be interacting in conjunction with other causative germ line polymorphisms found in linkage disequilibrium (LD). The susceptibility of cancer is multifactorial involving diverse genetic factors and pathways along with various conferred multiple loci, each with a small effect on cancer risk \[[@r39]\]. Hence, it is rationally inadequate to predict the cancer risk as a consequence of single genetic variation.

There were some limitations in the current meta-analysis which are acknowledged here - first, only english language studies were included; second, studies indexed by PubMed and EMBASE were included (this may have resulted in missing out on articles published in languages other than english and those indexed in other databases); third, our results were based on single-factor estimates without any adjustment for age, gender and other risk factors (e.g. smoking, drinking status etc.) because of the lack of original data. Though, there were several strengths in the current meta-analysis - first, we did not find any publication bias which indicates the statistical robustness of our results; second, our data extraction strategy was very stringent which was based on computer assisted and manual searches in order to make a trustworthy conclusion.

Conclusion
==========

The meta-analysis indicated that *DNMT3B* -149 C\>T gene polymorphism is not associated with cancer risk overall or in subgroup ethnicities - Asian and Caucasian populations. This limits the utility of this polymorphism as a predictor or screening marker of cancer risk in asymptomatic individuals. The heterogeneity in cancer poses a great challenge to researchers focusing on cancer pathogenesis and therapy. To further validate this negative association, large scale and well-designed studies in diverse populations incorporating the role of environmental factors are needed.
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###### 

Main characteristics of *DNMT3B* -149 C\>T based studies included in the meta-analysis.

  **First Author and Year**          **Cancer**       **Country**   **Ethnicity**   **Control**   **Cases**   **Source**
  ---------------------------------- ---------------- ------------- --------------- ------------- ----------- ---------------
  **Eftekhar *et al.*, 2014^a^**     Breast           Iran          Caucasian       138           100         Tissue
  **Succi *et al.*, 2014^b^**        Head and Neck    Brazil        Caucasian       488           237         Blood
  **Lao *et al.*, 2013^c^**          Hepatocellular   China         Asian           216           108         Blood
  **Mostowska *et al.*, 2013^d^**    Ovarian          Poland        Caucasian       180           159         Blood
  **Bao *et al.*, 2011^e^**          Colorectal       China         Asian           533           544         Blood
  **Hu *et al.*, 2010^f^**           Gastric          China         Asian           262           259         Blood
  **Karpinski *et al.*, 2010^g^**    Colorectal       Poland        Caucasian       140           186         Tissue
  **de Vogel *et al.*, 2009^h^**     Colorectal       Netherland    Caucasian       1,810         703         Mouth swab
  **Ezzikouri *et al.*, 2009^i^**    Hepatocellular   Morocco       Mixed           222           96          Blood
  **Iacopetta *et al.*, 2009^j^**    Colorectal       Australia     Caucasian       949           828         Buccal scrape
  **Liu *et al.*, 2008^k^**          Squamous Cell    USA           Caucasian       843           832         Blood
  **Chang *et al.*, 2008^l^**        Nasopharyngeal   Taiwan        Asian           250           259         Tissue
  **Fan *et al.*, 2008^m^**          Colorectal       China         Asian           308           137         Blood
  **Wu and Lin, 2007^n^**            Hepatocellular   China         Asian           140           100         Blood
  **Wang *et al.*, 2005^o^**         Gastric          China         Asian           294           212         Blood
  **Aung *et al.*, 2005^p^**         Gastric          Japan         Asian           247           152         Blood
  **Montgomery *et al.*, 2004^q^**   Breast           UK            Caucasian       258           352         Blood
  **Shen *et al.*, 2002^r^**         Lung             USA           Caucasian       340           319         Blood

^a^ Reference [@r11], ^b^ Reference [@r12], ^c^ Reference [@r13], ^d^ Reference [@r14], ^e^ Reference [@r15], ^f^ Reference [@r16], ^g^ Reference [@r17], ^h^ Reference [@r18], ^i^ Reference [@r19], ^j^ Reference [@r20], ^k^ Reference [@r21], ^l^ Reference [@r22], ^m^ Reference [@r23], ^n^ Reference [@r24], ^o^ Reference [@r25], ^p^ Reference [@r26], ^q^ Reference [@r27], ^r^ Reference [@r10].

###### 

Genotypic distribution of *DNMT3B*- 149 C\>T gene polymorphism based studies included in the meta-analysis.

  **Authors and Year**               **Controls**   **Cancer Cases**   **HWE^b^**                                   
  ---------------------------------- -------------- ------------------ ------------ ------ ----- ----- ----- ------ ---------
  **Eftekhar *et al.*, 2014^d^**     27             93                 18           0.46   27    47    26    0.49   \<0.001
  **Succi *et al.*, 2014^e^**        111            261                116          0.5    57    118   62    0.51   0.12
  **Lao *et al.*, 2013^f^**          0              6                  210          0.98   0     1     107   0.99   0.83
  **Mostowska *et al.*, 2013^g^**    51             91                 38           0.46   46    86    27    0.44   0.82
  **Bao *et al.*, 2011^h^**          0              12                 521          0.98   0     6     538   0.99   0.79
  **Karpinski *et al.*, 2010^i^**    45             67                 28           0.43   56    91    39    0.45   0.73
  **Hu *et al.*, 2010^j^**           0              3                  259          0.99   0     2     257   0.99   0.92
  **Ezzikouri *et al.*, 2009^k^**    37             63                 27           0.46   18    34    6     0.39   0.98
  **de Vogel *et al.*, 2009^l^**     597            895                318          0.42   240   348   115   0.41   0.57
  **Iacopetta *et al.*, 2009^m^**    274            463                212          0.46   247   414   167   0.45   0.53
  **Liu *et al.*, 2008^n^**          266            433                144          0.42   259   384   189   0.45   0.15
  **Chang *et al.*, 2008^o^**        0              0                  250          1      0     0     259   1      ND^c^
  **Fan *et al.*, 2008^p^**          0              4                  304          0.99   0     2     135   0.99   0.98
  **Wu and Lin, 2007^q^**            0              1                  139          0.99   0     3     97    0.98   0.96
  **Wang *et al.*, 2005^r^**         0              15                 279          0.97   0     7     205   0.98   0.65
  **Aung *et al.*, 2005^s^**         0              0                  247          1      0     0     152   1      ND
  **Montgomery *et al.*, 2004^t^**   120            173                59           0.41   82    116   60    0.45   0.8
  **Shen *et al.*, 2002^u^**         119            142                79           0.44   71    181   67    0.49   0.004

^a^ Minor allele frequency, ^b^ Hardy Weinberg equilibrium, ^c^ Not determined, ^d^ Reference [@r11], ^e^ Reference [@r12], ^f^ Reference [@r13], ^g^ Reference [@r14], ^h^ Reference [@r15], ^i^ Reference [@r17], ^j^ Reference [@r16], ^k^ Reference [@r19], ^l^ Reference [@r18], ^m^ Reference [@r20], ^n^ Reference [@r21], ^o^ Reference [@r22], ^p^ Reference [@r23], ^q^ Reference [@r24], ^r^ Reference [@r25], ^s^ Reference [@r26], ^t^ Reference [@r27], ^u^ Reference [@r10].

###### 

Statistics to test publication bias and heterogeneity in this meta-analysis.

  **Comparisons**            **Egger's Regression Analysis**   **Heterogeneity Analysis**   **Model Used for Meta-analysis**                               
  -------------------------- --------------------------------- ---------------------------- ---------------------------------- --------- ------- --------- --------
  **Overall population**                                                                                                                                   
  **T vs C**                 0.35                              -0.60 to 1.30                0.44                               17.53     0.28    14.46     Fixed
  **TT vs CC**               0.02                              -2.42 to 2.47                0.98                               14.22     0.11    36.73     Fixed
  **CT vs CC**               0.23                              -2.79 to 3.27                0.86                               22.28     0.008   59.61     Random
  **TT+CT vs CC**            0.22                              -2.32 to 2.76                0.84                               15.75     0.72    42.87     Fixed
  **TT vs CC+CT**            0.25                              -1.11 to 1.62                0.69                               29.53     0.014   49.2      Random
  **Asian population**                                                                                                                                     
  **T vs C**                 0.22                              -1.66 to 2.12                0.75                               4.77      0.44    \<0.001   Fixed
  **TT vs CC**               \-                                \-                           \-                                 \<0.001   1       \<0.001   Fixed
  **CT vs CC**               \-                                \-                           \-                                 \<0.001   1       \<0.001   Fixed
  **TT+CT vs CC**            \-                                \-                           \-                                 \<0.001   1       \<0.001   Fixed
  **TT vs CC+CT**            -0.07                             -2.61 to 2.46                0.93                               4.51      0.47    \<0.001   Fixed
  **Caucasian population**                                                                                                                                 
  **T vs C**                 0.005                             -2.07 to 2.08                0.99                               10.31     0.24    22.47     Fixed
  **TT vs CC**               -0.47                             -3.57 to 2.62                0.72                               12.18     0.09    42.54     Fixed
  **CT vs CC**               0.01                              -4.34 to 4.37                0.99                               21.99     0.003   68.17     Random
  **TT+CT vs CC**            -0.17                             -3.72 to 3.37                0.90                               14.89     0.037   53.01     Random
  **TT vs CC+CT**            -0.07                             -3.17 to 3.01                0.95                               22.54     0.004   64.52     Random

Note: (-) = 95%CI could not be calculated due to absence of genotype(s) in Asian population studies.

[^1]: *These authors contributed equally.*
